Denmark’s Novo Nordisk recently faced a setback in its experimental obesity treatment, CagriSema, which capped off a turbulent year for investors in the pharmaceutical industry. Despite this, shares in several other companies are on the rise as they make strides in their own obesity treatments.
Novo Nordisk has seen significant losses in market capitalization this year, while rival Eli Lilly’s shares have gained more than $170 billion in value due to high demand for its Zepbound drug. Smaller firms such as Zealand Pharma and Viking Therapeutics are also seeing increased success with their own weight loss treatments, causing their share prices to surge.
Source: https://www.bloomberg.com/news/articles/2024-12-23/hot-obesity-drug-market-will-keep-investors-gripped-next-year